Denali Therapeutics Inc’s filing revealed that its Chief Medical Officer Ho Carole unloaded Company’s shares for reported $0.25 million on Jan 06 ’25. In the deal valued at $20.22 per share,12,255 shares were sold. As a result of this transaction, Ho Carole now holds 178,580 shares worth roughly $2.61 million.
Then, Ho Carole sold 2,907 shares, generating $60,495 in total proceeds. Upon selling the shares at $20.81, the Chief Medical Officer now owns 175,673 shares.
Before that, Schuth Alexander O. sold 12,255 shares. Denali Therapeutics Inc shares valued at $247,796 were divested by the COFO and Secretary at a price of $20.22 per share. As a result of the transaction, Schuth Alexander O. now holds 247,215 shares, worth roughly $3.61 million.
Cantor Fitzgerald upgraded its Denali Therapeutics Inc [DNLI] rating to an Overweight from a a Neutral in a research note published recently. Deutsche Bank began covering DNLI with “Buy” recommendation on February 11, 2025. Robert W. Baird started covering the stock on January 07, 2025. It rated DNLI as “an Outperform”.
Price Performance Review of DNLI
On Tuesday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock jump 11.03% to $14.60. Over the last five days, the stock has gained 10.02%. Denali Therapeutics Inc shares have fallen nearly -28.36% since the year began. Nevertheless, the stocks have fallen -12.05% over the past one year. While a 52-week high of $33.33 was reached on 02/05/25, a 52-week low of $10.57 was recorded on 04/07/25. SMA at 50 days reached $15.84, while 200 days put it at $22.50.
Levels Of Support And Resistance For DNLI Stock
The 24-hour chart illustrates a support level at 13.79, which if violated will result in even more drops to 12.97. On the upside, there is a resistance level at 15.04. A further resistance level may holdings at 15.47. The Relative Strength Index (RSI) on the 14-day chart is 54.17, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.72, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 5.40%. Stochastics %K at 68.70% indicates the stock is a holding.
How much short interest is there in Denali Therapeutics Inc?
A steep rise in short interest was recorded in Denali Therapeutics Inc stocks on 2025-03-31, growing by 2.55 million shares to a total of 11.44 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 8.89 million shares. There was a rise of 22.29%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 03, 2025 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating .
